Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Malaria Research & Training Center, Faculty of Medicine, Pharmacy and Dentistry, University of Sciences Techniques and Technologies of Bamako, P.O Box 1805, Bamako, Mali.
Reprod Health. 2020 Mar 17;17(1):39. doi: 10.1186/s12978-020-0890-7.
In sub-Saharan Africa, malaria continues to scourge the population and is the primary cause of morbidity and mortality in young children and pregnant women. As current preventative measures such as intermittent preventive treatment and use of insecticide-treated nets provide incomplete protection, several malaria vaccines are currently under development, including one to specifically prevent pregnancy malaria. Prior to conducting vaccine trials, it is important to obtain background information on poor pregnancy outcomes in the target population to establish a baseline.
Pregnant women presenting at community health care centers for antenatal care were recruited to the study. Gestational age was determined by ultrasound examination following recruitment. Antenatal care and pregnancy outcome information were collected during a visit 4-8 weeks post-delivery.
One thousand eight hundred fifty women completed the study, and analysis included 1814 women after excluding multiple gestations (n = 26) and missing/incomplete data (n = 10). The percentage (95% CI) of adverse pregnancy outcomes is as follows: miscarriage, 0.28% (0.04-0.52); stillbirth, 1.93% (1.30-2.56); early neonatal death, 1.65% (1.03-2.24); late neonatal death, 0.39%, (0.10-0.68); and preterm delivery (PTD), 4.74% (3.76-5.73). The percentages of early and late neonatal deaths and PTD were significantly higher (p < 0.01) in primigravid compared to multigravid women. In primigravidae, 3.1, 1.1 and 7.1% of pregnancies resulted in early neonatal death, late neonatal death and PTD, respectively, while these outcomes in multigravidae were 1.0, 0.1 and 2.7%, respectively. Major malformations were identified in 4 newborns.
Low gravidity and young age predict perinatal death and PTD. The information collected here can be used as a baseline for adverse pregnancy outcomes in future vaccine trials in pregnant women.
在撒哈拉以南非洲,疟疾继续肆虐,是导致幼儿和孕妇发病和死亡的主要原因。由于目前的预防措施,如间歇性预防治疗和使用驱虫蚊帐,提供的保护并不完全,目前正在开发几种疟疾疫苗,包括一种专门预防妊娠疟疾的疫苗。在进行疫苗试验之前,重要的是要获得目标人群中不良妊娠结局的背景信息,以建立基线。
招募在社区保健中心进行产前护理的孕妇参加这项研究。妊娠年龄通过招募后的超声检查确定。在产后 4-8 周的一次就诊中收集产前护理和妊娠结局信息。
1850 名妇女完成了这项研究,在排除多胎妊娠(n=26)和缺失/不完整数据(n=10)后,对 1814 名妇女进行了分析。不良妊娠结局的百分比(95%CI)如下:流产,0.28%(0.04-0.52);死产,1.93%(1.30-2.56);新生儿早期死亡,1.65%(1.03-2.24);新生儿晚期死亡,0.39%(0.10-0.68);早产(PTD),4.74%(3.76-5.73)。初产妇的早期和晚期新生儿死亡和 PTD 百分比明显高于多产妇(p<0.01)。在初产妇中,分别有 3.1%、1.1%和 7.1%的妊娠导致新生儿早期死亡、晚期死亡和 PTD,而多产妇中这些结果分别为 1.0%、0.1%和 2.7%。4 名新生儿发现有重大畸形。
低孕次和年轻是围产期死亡和 PTD 的预测因素。这里收集的信息可作为未来孕妇疫苗试验中不良妊娠结局的基线。